Paloma Wang

Corporate

Admitted in Hong Kong and England & Wales. Currently practising in Hong Kong.

Recent publications include:

HKEX and SFC Reduce Barriers for Specialist Technology Company IPOs and De-SPACs, August 2024;

HKEX Consults on New Corporate Governance Reforms, July 2024

HKEx Publishes Consultation Conclusions on Enhancing Climate-Related Disclosure, May 2024

HKEx Announces Consultation Conclusion for New Treasury Shares Rules, April 2024

Paloma Wang is co-head of the firm’s China practice, focusing on public listings and other corporate matters. She represents both issuers and underwriters in initial public offerings on the Hong Kong Stock Exchange, advising investors and corporates on private equity investments and counseling listed issuers on compliance, general corporate and regulatory matters.

Ms. Wang advised on the three largest Hong Kong listings in 2020 (for JD.com, Inc.; JD Health International Inc.; and NetEase, Inc.), the second largest Hong Kong IPO in 2021 (for JD Logistics, Inc.), four of the five largest Hong Kong secondary listings in 2020 (for JD.com, Inc.; NetEase, Inc.; New Oriental Education & Technology Group Inc.; and ZTO Express (Cayman) Inc.), and all of the Hong Kong secondary listings in 2021 (Autohome Inc.; Baidu, Inc.; Bilibili Inc.; Trip.com Group Limited; and Weibo Corporation).

City University of Hong Kong

PCLL

2003

University of Oxford

B.A. Law

2002

China University of Politics and Law

B.A.

1999

IPO Lawyer of the Year

ALM Asia Legal Awards

2021

Rising Star Partner for Equity Capital Markets

IFLR1000

2022

Ms. Wang is a market leader in advising in the biotech and life sciences sector, TMT/new economy companies with WVR structures and "Homecoming" companies with secondary listings in Hong Kong.

Hong Kong